V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

Rigel Pharmaceuticals Executive Compensation (FY25)

RIGL · Executive and director compensation, fiscal 2023 to 2025

The Rigel Pharmaceuticals brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Data as of September 7, 2026Latest filing (DEF 14A): April 3, 2026
3 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Rigel Pharmaceuticals brief$1,500Get the executive brief
192 figures on this page, cited to the filing that reported them. See the citations
Chief executive, fiscal 2025
◇
Raul Rodriguez
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Raul Rodriguez: $2,998,688 → $4,658,805 (55.4% higher)
CEO pay ratio: 10:1 → 14:1 (40.0% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Rigel Pharmaceuticals' chief executive and what were they paid?
Total compensation for Raul Rodriguez, President and Chief Executive Officer, came to $4,658,805 in fiscal 2025. Compared with the $2,998,688 reported for fiscal 2024, Rodriguez's total was 55.4% higher.
Which companies are in Rigel Pharmaceuticals' peer group?
The disclosed peer group includes 2seventy bio, Agenus Inc., Akebia Therapeutics Inc., Arcturus Therapeutics Holdings Inc. and Assertio Holdings, Inc., among others.
What is Rigel Pharmaceuticals' chief executive pay ratio?
The company reported a chief executive pay ratio of 14:1 for fiscal 2025, against median employee compensation of $329,269.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Raul Rodriguez
President and Chief Executive Officer
◇—◇◇◇—◇◇
David Santos
Executive Vice President and Chief Commercial Officer
◇—◇◇◇—◇◇
Dean Schorno
Executive Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Raymond Furey
Executive Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary
◇———◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Raul Rodriguez
President and Chief Executive Officer
◇—◇◇◇—◇◇
David Santos
Executive Vice President and Chief Commercial Officer
◇—◇◇◇—◇◇
Dean Schorno
Executive Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Raymond Furey
Executive Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary
◇—◇◇◇—◇◇
Lisa Rojkjaer
Executive Vice President and Chief Medical Officer
◇◇—◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Raul Rodriguez
President and Chief Executive Officer
◇—◇◇◇—◇◇
David Santos
Executive Vice President and Chief Commercial Officer
◇—◇◇◇—◇◇
Lisa Rojkjaer
Executive Vice President and Chief Medical Officer
◇—◇◇◇—◇◇
Dean Schorno
Executive Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Raymond Furey
Executive Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
David SantosRSU——————◇
David SantosOption——————◇
Dean SchornoOption——————◇
Dean SchornoRSU———◇——◇
Lisa RojkjaerRSU——————◇
Lisa RojkjaerOption——————◇
Raul RodriguezRSU———◇——◇
Raul RodriguezOption——————◇
Raymond FureyRSU——————◇
Raymond FureyOption——————◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Raymond FureyOption◇—◇1/24/34
Option◇—◇12/8/32
RSU◇◇——
RSU◇◇——
Option◇—◇1/29/35
Raul RodriguezRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇1/24/32
RSU◇◇——
Option◇—◇1/29/35
Option◇—◇1/23/34
Option◇—◇1/26/33
David SantosRSU◇◇——
RSU◇◇——
Option◇—◇1/26/33
RSU◇◇——
Option◇—◇1/29/35
Option◇—◇1/24/34
Option◇—◇1/24/32
RSU◇◇——
Dean SchornoRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇1/24/32
Option◇—◇1/29/35
RSU◇◇——
Option◇—◇1/26/33
Option◇—◇1/24/34
Lisa RojkjaerRSU◇◇——
Option◇—◇1/29/35
Option◇—◇3/27/34
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Mark W. Frohlich, M.D
◇◇◇———◇
Gregg A. Lapointe
Board chair
◇◇◇———◇
Jane Wasman, J.D
◇◇◇———◇
Kamil Ali-Jackson
◇◇◇———◇
Walter H. Moos, Ph.D
◇◇◇———◇
Alison L. Hannah, M.D
◇◇◇———◇
Michael P. Miller and Raul R. Rodriguez served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • 2seventy bio TSVT
  • Agenus Inc. AGEN
  • Akebia Therapeutics Inc. AKBA
  • Arcturus Therapeutics Holdings Inc. ARCT
  • Assertio Holdings, Inc. ASRT
  • Coherus BioSciences, Inc. CHRS
  • Esperion Therapeutics, Inc. ESPR
  • Heron Therapeutics, Inc. HRTX
  • Karyopharm Therapeutics Inc. KPTI
  • MacroGenics, Inc. MGNX
  • Nektar Therapeutics NKTR
  • Omeros Corporation OMER
  • Puma Biotechnology, Inc. PBYI
  • Sangamo Therapeutics, Inc. SGMO
  • Theravance Biopharma, Inc. TBPH
  • Travere Therapeutics, Inc. TVTX
  • UroGen Pharma Ltd. URGN
  • Xeris Biopharma Holdings, Inc. XERS

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Rigel Pharmaceuticals files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Rigel Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Rigel Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Rigel Pharmaceuticals' disclosed peer group is defensible, who names Rigel Pharmaceuticals back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
192 figures on this page, cited to the filing that reported them.
192 cited to the filing

Documents cited

  1. 0001034842-26-000023
    2025 SUMMARY COMPENSATION TABLE · DIRECTOR COMPENSATION · DIRECTOR COMPENSATION FOR FISCAL YEAR 2025 · GRANTS OF PLAN-BASED AWARDS FOR FISCAL YEAR 2025 · and 1 more section
  2. 0001140361-25-013250
    2024 SUMMARY COMPENSATION TABLE
  3. 0001140361-24-019133
    2023 SUMMARY COMPENSATION TABLE
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Rigel Pharmaceuticals executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/RIGL (accessed 2026).
Short form: data: Velarion

The Rigel Pharmaceuticals brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Rigel Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Rigel Pharmaceuticals discloses

The companies named in RIGL's own disclosed peer group.

Agenus Inc.Akebia Therapeutics Inc.Arcturus Therapeutics Holdings Inc.Coherus BioSciences, Inc.Esperion Therapeutics, Inc.Heron Therapeutics, Inc.Karyopharm Therapeutics Inc.MacroGenics, Inc.Nektar TherapeuticsOmeros CorporationPuma Biotechnology, Inc.Theravance Biopharma, Inc.Travere Therapeutics, Inc.UroGen Pharma Ltd.Xeris Biopharma Holdings, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy